Home Cart Sign in  
Chemical Structure| 163042-96-4 Chemical Structure| 163042-96-4

Structure of Namodenoson
CAS No.: 163042-96-4

Chemical Structure| 163042-96-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

2-Cl-IB-MECA is a highly selective A3 adenosine receptor agonist with Ki value of 0.33nM, displaying 2500- and 1400-fold selectivity over A1 and A2A receptors, respectively.

Synonyms: 2-Cl-IB-MECA; CF-102; Chloro-IB-MECA

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Namodenoson

CAS No. :163042-96-4
Formula : C18H18ClIN6O4
M.W : 544.73
SMILES Code : O=C([C@H]1O[C@@H](N2C=NC3=C(NCC4=CC=CC(I)=C4)N=C(Cl)N=C23)[C@H](O)[C@@H]1O)NC
Synonyms :
2-Cl-IB-MECA; CF-102; Chloro-IB-MECA
MDL No. :MFCD01861178
InChI Key :IPSYPUKKXMNCNQ-PFHKOEEOSA-N
Pubchem ID :3035850

Safety of Namodenoson

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Namodenoson

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HEK293A cells 100 nM 1 hour To measure the activation of adenosine receptor subtypes, Namodenoson showed unparalleled potency and selectivity for A3R. Nat Commun. 2024 Nov 7;15(1):9294
primary retinal microglial cells 1 µM 4 h To evaluate the effect of A3R activation on EHP-induced cell proliferation. Results showed that A3R activation significantly inhibited EHP-induced cell proliferation. Int J Mol Sci. 2020 Sep 30;21(19):7218
BV-2 cells 1 µM 24 h To evaluate the effect of A3R activation on EHP-induced phagocytic activity. Results showed that A3R activation significantly reduced EHP-induced phagocytic activity. Int J Mol Sci. 2020 Sep 30;21(19):7218
BV-2 cells 1 µM 4 h To evaluate the effect of A3R activation on EHP-induced cell migration. Results showed that A3R activation significantly inhibited EHP-induced cell migration. Int J Mol Sci. 2020 Sep 30;21(19):7218
BV-2 cells 1 µM 24 h To evaluate the effect of A3R activation on EHP-induced iNOS expression. Results showed that A3R activation significantly reduced EHP-induced iNOS expression. Int J Mol Sci. 2020 Sep 30;21(19):7218
Hep-3B hepatocellular carcinoma cells 20 nM and 20 µM 24 hours Analysis of cell cycle progression revealed that 20 µM 2‑cl‑IB‑ME cA increased the number of cells in the G1 phase and the subG1 population, indicating increased apoptosis. Int J Mol Med. 2022 Mar;49(3):31
JoPaca-1 pancreatic cancer cells 20 nM and 20 µM 24 hours Analysis of cell cycle progression revealed that 20 µM 2‑cl‑IB‑ME cA increased the number of cells in the G1 phase and the subG1 population, indicating increased apoptosis. Int J Mol Med. 2022 Mar;49(3):31
Mouse ADPKD kidney cells (PH2 and PN24) 100 nM 24 hours Evaluate the effect of Cl-IB-MECA on CREB activity, showing significant reductions in CREB activity Clin Exp Nephrol. 2017 Apr;21(2):203-211
Human ADPKD kidney cells (9.7 and 9.12) 100 nM 24 hours Evaluate the effect of Cl-IB-MECA on CREB, mTOR, and ERK activity, showing significant reductions in CREB and ERK activity Clin Exp Nephrol. 2017 Apr;21(2):203-211
Human normal kidney cells (4/5) 100 nM 24 hours Evaluate the effect of Cl-IB-MECA on CREB activity, showing no significant changes in CREB activity in normal kidney cells Clin Exp Nephrol. 2017 Apr;21(2):203-211
HUCCT1 10 μM 72 hours To study the antiproliferative effects of Namodenoson on HUCCT1 cells Gastro Hep Adv. 2024 Nov 20;4(3):100590
HepG2 2.5, 5, 10 μM 24 hours To study the antiproliferative effects of Namodenoson on HepG2 cells and its impact on HDAC1-11 mRNA expression Gastro Hep Adv. 2024 Nov 20;4(3):100590
LX2 cells 10 nM 24, 48, 72 hours To evaluate the effect of Namodenoson on LX2 cell proliferation, results showed that A3R agonist inhibited LX2 cell proliferation. Front Pharmacol. 2024 Sep 3;15:1424624
BxPC-3 pancreatic carcinoma cells 5-20 nM 24 hours Namodenoson significantly inhibited BxPC-3 cell growth with inhibition rates of 49.7%±8.2%, 66.3%±10.5%, and 82.7%±7.1% (5 nM, 10 nM, and 20 nM, respectively). This inhibition was mitigated by the A3AR antagonist MRS1523. Biomolecules. 2023 Oct 27;13(11):1584

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice CCl4-induced liver fibrosis model Intraperitoneal injection 200 μg/kg Twice weekly for 6 weeks To evaluate the effect of Namodenoson on liver fibrosis, results showed that A3R agonist alleviated liver fibrosis, characterized by decreased ALT and AST levels, reduced pathological liver damage, and collagen deposition. Front Pharmacol. 2024 Sep 3;15:1424624
Sprague-Dawley rats Laser-induced ocular hypertension model Intravitreal injection 1.2 µM, 5 µl Single injection, lasted for 7 days 2-Cl-IB-MECA protects retinal ganglion cells from degeneration induced by ocular hypertension via A3R activation, improving retinal function and axonal transport. Cell Death Dis. 2020 May 27;11(5):401
Mouse Pkd1flox/−:Ksp-Cre ADPKD model Intraperitoneal injection 0.2 mg/kg Once daily for 7 days Evaluate the effect of Cl-IB-MECA on CREB, mTOR, and ERK activity, showing significant reductions in CREB, mTOR, and ERK activity, but no changes in kidney weight Clin Exp Nephrol. 2017 Apr;21(2):203-211
Nude mice (Balb/C) Subcutaneous BxPC-3 pancreatic carcinoma model Oral 10 µg/kg Twice daily for 35 days Namodenoson significantly inhibited pancreatic carcinoma tumor growth with an inhibition rate of 67.7%±15.2%. Biomolecules. 2023 Oct 27;13(11):1584

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.84mL

0.37mL

0.18mL

9.18mL

1.84mL

0.92mL

18.36mL

3.67mL

1.84mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories